Safety of Dual-Antiplatelet Therapy After Myocardial Infarction Among Patients With Chronic Kidney Disease

Myocardial Infarction

High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patients

Am Heart J.

Fu EL, Franko MA, Obergfell A, Dekker FW, Gabrielsen A, Jernberg T, Carrero JJ

doi: 10.1016/j.ahj.2019.06.019.

Heart, Artery and Coronary DiseasesThrombosis and StrokeTherapy and Intervention

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)

Eur Heart J.

Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL

doi: 10.1093/eurheartj/ehx419.

Myocardial InfarctionTherapy and Intervention

Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial

BMJ.

Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, Zurakowski A, Schotborgh CE, Hoorntje JCA, Eek CH, Cook S, Togni M, Meuwissen M, van Royen N, van Vliet R, Wedel H, Delewi R, Zijlstra F

doi: 10.1136/bmj.k3793.

Heart, Artery and Coronary Diseases

Efficacy and Safety of High Potent P2Y12 Inhibitors Prasugrel and Ticagrelor in Patients With Coronary Heart Disease Treated With Dual Antiplatelet Therapy: A Sex-Specific Systematic Review and Meta-Analysis

J Am Heart Assoc.

Schreuder MM, Badal R, Boersma E, Kavousi M, Roos-Hesselink J, Versmissen J, Visser LE, Roeters van Lennep JE

doi: 10.1161/JAHA.119.014457.

Myocardial InfarctionFurther Publications

Oxygen therapy in suspected acute myocardial infarction and concurrent normoxemic chronic obstructive pulmonary disease: a prespecified subgroup analysis from the DETO2X-AMI trial

Eur Heart J Acute Cardiovasc Care.

Andell P, James S, Östlund O, Yndigegn T, Sparv D, Pernow J, Jernberg T, Lindahl B, Herlitz J, Erlinge D, Hofmann R

doi: 10.1177/2048872619848978.

Heart Failure

Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease

JACC Heart Fail.

Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, O'Meara E, Pitt B, Shah SJ, Voors AA, Pfeffer MA, Solomon SD, Desai AS

doi: 10.1016/j.jchf.2018.

RECOMMENDED

Lipid-Lowering DrugsFurther Publications

Statin therapy among chronic kidney disease patients presenting with acute coronary syndrome

Atherosclerosis.

Natanzon SS, Matetzky S, Beigel R, Iakobishvili Z, Goldenberg I, Shechter M, Acute Coronary Syndrome Israel Survey (ACSIS) investigators

doi: 10.1016/

Therapy and Intervention

The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial

Clin Res Cardiol.

Ono M, Chichareon P, Tomaniak M, Kawashima H, Takahashi K, Kogame N, Modolo R, Hara H, Gao C, Wang R, Walsh S, Suryapranata H, da Silva PC, Cotton J, Koning R, Akin I, Rensing BJWM, Garg S, Wykrzykowska JJ, Piek JJ, Jüni P, Hamm C, Steg PG, Valgimigli M, Windecker S, Storey RF, Onuma Y, Vranckx P, Serruys PW

doi: 10.1007/s00392-020-01604-1.

Atrial FibrillationHeart, Artery and Coronary DiseasesMyocardial InfarctionThrombosis and StrokeTherapy and Intervention

Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation

J Am Coll Cardiol.

Lee CJ, Pallisgaard JL, Olesen JB, Carlson N, Lamberts M, Gislason GH, Torp-Pedersen C, Brandes A, Husted SE, Johnsen SP, Hansen ML

doi: 10.1016/j.jacc.2017.04.033.

Related content